Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
UN Security Council rejects Russia
UNITED NATIONS (AP) — The United States said Monday that Russia last week launched a satellite that2024-05-22It would take until 2040 to repair all homes destroyed so far in Gaza, UN report says
If the Israel-Hamas war stopped today, it would still take until 2040 to rebuild all the homes that2024-05-22Chinese researchers start 2024 Arctic expedition at Yellow River Station
This photo taken by a mobile phone on April 30, 2024 shows members of Chinese Arctic expedition team2024-05-22China allocates disaster relief funds for Jiangxi, Guangdong, Guangxi
An aerial drone photo taken on April 21, 2024 shows a view of the Beijiang River tributary in Wujian2024-05-22How Robert F. Kennedy Jr. could make the first debate stage
PHOENIX (AP) — Robert F. Kennedy Jr. has long argued that the biggest hurdle of his presidential cam2024-05-22Media forum in Beijing discusses AI development
Focusing on the development of artificial intelligence (AI), the third CMG Forum was held on Monday2024-05-22
atest comment